DUBLIN, Ireland, October 20 /PRNewswire/ -- Research and Markets
(http://www.researchandmarkets.com/reports/c26190) has announced the addition
of Cardiovascular Drug Delivery - Technologies, Markets and Companies to
their offering.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )
Drug delivery to the cardiovascular system is different from delivery to
other systems because of the anatomy and physiology of the vascular system;
it supplies blood and nutrients to all organs of the body. Drugs can be
introduced into the vascular system for systemic effects or targeted to an
organ via the regional blood supply. In addition to the usual formulations of
drugs such as controlled release, devices are used as well. This report
starts with an introduction to molecular cardiology and discusses its
relationship to biotechnology and drug delivery systems.
Drug delivery to the cardiovascular system is approached at three levels:
(1) Routes of drug delivery;
(2) Formulations; and finally
(3) Applications to various diseases.
Formulations for drug delivery to the cardiovascular system range from
controlled release preparations to delivery of proteins and peptides. Cell
and gene therapies, including antisense and RNA interference, are described
in full chapters as they are the most innovative methods of delivery of
therapeutics. Various methods of improving systemic administration of drugs
for cardiovascular disorders are described including use of nanotechnology.
Cell-selective targeted drug delivery has emerged as one of the most
significant areas of biomedical engineering research, to optimize the
therapeutic efficacy of a drug by strictly localizing its pharmacological
activity to a pathophysiologically relevant tissue system. These concepts
have been applied to targeted drug delivery to the cardiovascular system.
Devices for drug delivery to the cardiovascular system are also described.
Role of drug delivery in various cardiovascular disorders such as
myocardial ischemia, hypertension and hypercholesterolemia is discussed. Some
of the preparations and technologies are also applicable to peripheral
arterial diseases. Controlled release systems are based on
chronopharmacology, which deals with the effects of circadian biological
rhythms on drug actions. A full chapter is devoted to drug-eluting stents as
treatment for restenosis following stenting of coronary arteries. Fifteen
companies are involved in drug-eluting stents.
New cell-based therapeutic strategies are being developed in response to
the shortcomings of available treatments for heart disease. Potential repair
by cell grafting or mobilizing endogenous cells holds particular attraction
in heart disease, where the meager capacity for cardiomyocyte proliferation
likely contributes to the irreversibility of heart failure. Cell therapy
approaches include attempts to reinitiate cardiomyocyte proliferation in the
adult, conversion of fibroblasts to contractile myocytes, conversion of bone
marrow stem cells into cardiomyocytes, and transplantation of myocytes or
other cells into injured myocardium.
Advances in molecular pathophysiology of cardiovascular diseases have
brought gene therapy within the realm of possibility as a novel approach to
treatment of these diseases. It is hoped that gene therapy will be less
expensive and affordable because the techniques involved are simpler than
those involved in cardiac bypass surgery, heart transplantation and stent
implantation. Gene therapy would be a more physiologic approach to deliver
vasoprotective molecules to the site of vascular lesion. Gene therapy is not
only a sophisticated method of drug delivery; it may at time need drug
delivery devices such as catheters for transfer of genes to various parts of
the cardiovascular system.
The cardiovascular drug delivery markets are estimated for the years 2005
to 2015 on the basis of epidemiology and total markets for cardiovascular
therapeutics. The estimates take into consideration the anticipated advances
and availability of various technologies, particularly drug delivery devices
in the future. Markets for drug-eluting stents are calculated separately.
Role of drug delivery in developing cardiovascular markets is defined and
unmet needs in cardiovascular drug delivery technologies are identified.
Selected 65 companies that either develop technologies for drug delivery
to the cardiovascular system or products using these technologies are
profiled and 65 collaborations between companies are tabulated. The
bibliography includes 120 selected references from recent literature on this
topic. The report is supplemented with 26 tables and 5 figures
For more information visit
http://www.researchandmarkets.com/reports/c26190
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353-1-4100-980
SOURCE Research and Markets
 back to top
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH
CONTACT:
Laura Wood, Senior Manager, Research and
Markets, press@researchandmarkets.com, Fax: +353-1-4100-980
|
